TG Therapeutics Inc. (TGTX) announced Monday morning that its Phase 3 trial of TG-1101 plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia met its primary endpoint.
from RTT - Before the Bell http://ift.tt/2lS20Ju
via IFTTT
No comments:
Post a Comment